Engineering and characterization of a novel fusion protein incorporating B7.2 and an Anti-ErbB-2 single-chain antibody fragment for the activation of jurkat T cells

Journal of Immunotherapy

Volumn 24, Issue 1, 2001, Pages 27-36

  Marshall, K W ^a   Marks, J D ^a  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

B7.2; Cancer immunotheraphy; ErbB 2; Single chain Fv; T cell costimulation

Indexed keywords

CD86 ANTIGEN; HYBRID PROTEIN; ONCOPROTEIN;

ANTIGEN BINDING; ARTICLE; CANCER IMMUNOTHERAPY; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, CD; ANTIGENS, CD86; CHO CELLS; CRICETINAE; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; JURKAT CELLS; KINETICS; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; PROTEIN ENGINEERING; RABBITS; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; SURFACE PLASMON RESONANCE; TRANSFECTION;

EID: 0035135433     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200101000-00004     Document Type: Article

References (27)

1. A cell culture model for T lymphocyte clonal anergy
2. The two-signal model of lymphocyte activation twenty-one years later
3. The costimulatory function of antigen-presenting cells
4. The role of the CD28 receptor during T cell responses to antigen
5. The B7 and CD28 receptor families
6. Costimulation of antitumor immunity by the B7 counter receptor for the T lymphocyte molecules CD28 and CTLA-4
7. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells
8. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules
9. T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: An important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells
10. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors
11. Major histocompatibility complex class II+ B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice
12. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules
13. T-Helper- and accessory cell-independent cytotoxic responses to human tumor cells transfected with a B7 retroviral vector
14. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
15. Expression of c-erbB-2 (HER-2/neu) oncoprotein in human prostatic cancer
16. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site
17. Multi-subunit proteins on the surface of filamentous phage: Methodologies for displaying antibody (Fab) heavy and light chains
18. Engineering disulfide-linked single-chain Fv dimers [(sFv')2] with improved solution and targeting properties: Anti-digoxin 26-10 (sFv')2 and anti-c-erbB-2 741F8 (sFv')2 made by protein folding and bonded through C-terminal cysteinyl peptides
19. Genetic approach to facilitate purification of recombinant proteins with a novel metal chelate absorbent
20. Immobilization of proteins to a carboxymethyldextran mondified gold surface for BIAcore in surface plasmon resonance
21. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation
22. A B7.1 antibody fusion protein retains antibody specificity and ability to activate via the T cell costimulatory pathway
23. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity
24. Specific targeting of in vitro-activated human antitumor effector cells using anti-CD3 x anti-c-erbB-2 bispecific antibody
25. Costimulation of T cell proliferation by a chimeric B7-2 antibody fusion protein specifically targeted to cells expressing the erbB2 proto-oncogene
26. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies
27. The immunogenicity of chimeric antibodies